Galuteolin

Galuteolin

SCHEMBL149118

O=c1cc(-c2ccc(O)c(O)c2)oc2cc(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 1.00
KMT2A Q03164 5/20 1.00
KDM4E B2RXH2 5/20 1.00
TDP1 Q9NUW8 3/20 1.00
L3MBTL1 Q9Y468 3/20 1.00
MAPT P10636 3/20 1.00
TNF P01375 2/20 1.00
ALDH1A1 P00352 2/20 1.00
HSD17B10 Q99714 1/20 1.00
RECQL P46063 1/20 1.00
IL2 P60568 1/20 1.00
SMN1; SMN2 Q16637 2/20 0.85
SLCO2B1 O94956 2/20 0.85
KDM1A O60341 3/20 0.81
XDH P47989 3/20 0.78
KDM4A O75164 1/20 0.75
KDM4C Q9H3R0 1/20 0.75
EPHX2 P34913 2/20 0.73
POLB P06746 3/20 0.63
GAA P10253 3/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Galuteolin SCHEMBL30282117 1.00 MEN1 (1.00) MEN1KMT2AKDM4ETDP1L3MBTL1
Galuteolin SCHEMBL242535 1.00 MEN1 (1.00) MEN1KMT2AKDM4ETDP1L3MBTL1
Galuteolin SCHEMBL19523005 1.00 MEN1 (1.00) MEN1KMT2AKDM4ETDP1L3MBTL1
Galuteolin SCHEMBL149119 1.00 MEN1 (1.00) MEN1KMT2AKDM4ETDP1L3MBTL1
Galuteolin SCHEMBL2126750 1.00 MEN1 (1.00) MEN1KMT2AKDM4ETDP1L3MBTL1
Galuteolin SCHEMBL16755609 1.00 MEN1 (1.00) MEN1KMT2AKDM4ETDP1L3MBTL1
Galuteolin SCHEMBL17232556 1.00 MEN1 (1.00) MEN1KMT2AKDM4ETDP1L3MBTL1
Galuteolin SCHEMBL4984197 1.00 MEN1 (1.00) MEN1KMT2AKDM4ETDP1L3MBTL1
Galuteolin SCHEMBL22510086 1.00 MEN1 (1.00) MEN1KMT2AKDM4ETDP1L3MBTL1
Galuteolin SCHEMBL29374275 1.00 MEN1 (1.00) MEN1KMT2AKDM4ETDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1852 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122080093-A Compounds effective in treating liver toxicity and fatty liver disease and uses thereof 2026-05-26 CN claimed
WO-2026087503-A1 NON-THERAPEUTIC USE OF ARONIA EXTRACT FOR ENHANCING EXECUTIVE FUNCTION BIOACTOR BV (NL) 2026-04-30 WO claimed
EP-4626258-A1 NON-THERAPEUTIC USE OF AN ARONIA BERRY EXTRACT BioActor B.V. (NL) 2025-10-08 EP claimed
EP-4609911-A2 COMPOUNDS EFFECTIVE IN TREATING HEPATOTOXICITY AND FATTY LIVER DISEASES AND USES THEREOF Sinew Pharma Inc. (TW) 2025-09-03 EP claimed
US-20250228794-A1 HOMOVANILLYL ALCOHOL (HVA), HVA ISOMER, METHODS OF MAKING COMPOSITIONS COMPRISING SUCH COMPOUNDS, AND METHODS USING SUCH COMPOUNDS NESTLE SA (CH) 2025-07-17 US claimed
CN-120131558-A Multifunctional particles for aquatic product cultivation and processing and preparation method thereof 浙江海洋大学 2025-06-13 CN claimed
CN-120053656-A Medicine target spot of cynaroside C for resisting ciliate, application and medicine for killing ciliate 暨南大学 2025-05-30 CN claimed
CN-119524140-A Compositions and methods for preventing or treating adipose pancreas, ameliorating pancreatic lesions, diabetes, or other related conditions caused by adipose pancreas 雅各生技有限公司 2025-02-28 CN claimed
US-20250064094-A1 COMPOSITIONS FOR FOOD COLORING AND ANTIOXIDANT SUPPLEMENTATION DERIVED FROM SORGHUM RedLeaf Biologics, Inc. (US) 2025-02-27 US claimed
EP-4472625-A1 COMPOSITIONS FOR FOOD COLORING AND ANTIOXIDANT SUPPLEMENTATION DERIVED FROM SORGHUM Redleaf Biologics, Inc. (US) 2024-12-11 EP claimed
US-20020165207-A1 Compositions and methods for the treatment of diabetic neuropathy QUIGLEY CORPORATION, THE 2002-11-07 US claimed
US-20020115618-A1 Method and composition for the topical treatment of diabetic neuropathy QUIGLEY CORPORATION, THE 2002-08-22 US claimed
EP-1223928-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS Prendergast, Patrick Thomas (IE) 2002-07-24 EP claimed
WO-2002049575-A2 METHOD AND COMPOSITION FOR THE TREATMENT OF DIABETIC NEUROPATHY THE QUIGLEY CORPORATION (US) 2002-06-27 WO claimed
WO-2001003681-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS PRENDERGAST PATRICK T (IE) 2001-01-18 WO claimed
US-6054128-A COMPRISING VITAMIN B6, VITAMIN B12 AND FOLIC ACID FOR REDUCING THE SERUM HOMOCYSTEINE LEVEL, ANTIOXIDANTS TO REDUCE OXIDATION OF LOW DENSITY LIPOPROTEINS; SELENIUM TO REDUCE PLATELET AGGREGATION AND MODULATE PROSTAGLANDIN SYNTHESIS WAKAT DIANE (US) 2000-04-25 US claimed
EP-0980203-A1 ANTIMICROBIAL PREVENTION AND TREATMENT OF HUMAN IMMUNEDEFICIENCY VIRUS AND OTHER INFECTIOUS DISEASES Squires, Meryl (US) 2000-02-23 EP claimed
WO-1998042188-A1 ANTIMICROBIAL PREVENTION AND TREATMENT OF HUMAN IMMUNEDEFICIENCY VIRUS AND OTHER INFECTIOUS DISEASES SQUIRES MERYL (US) 1998-10-01 WO claimed
EP-0633022-B1 Chondroprotective flavones KUREHA CHEMICAL IND CO LTD (JP) 1997-02-19 EP claimed
EP-0633022-A2 Chondroprotective flavones KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) 1995-01-11 EP claimed